Introduction
During the last decade there has been a radical change in the direction of psychiatric research with an increasing emphasis on the neurobiology. Neuropharmacology led the way during the previous 10-15 years. Then our understanding of the mechanisms involved in the transmission of information at the neuro synapse made rapid advances because of our ability to analyse and measure biochemical activity in extracted brain material. The explosion which has occurred in the methods and understanding of neurobiology during the past 15 years has been phenomenal.
For example, during the past year, molecular biologists working with clinicians have identified a site on chromosome 11 linked to the insulin gene, believed to be responsible for the inheritance ofmanicdepressive psychoses in some family trees. The site is close to the gene which encodes for tyrosine hydroxylase which is involved in dopamine synthesis'. Another group of molecular biologists have located a site on the 21st chromosome responsible for the production of amyloid substances which make up the bulk ofplaques found in the brains ofpatients with Alzheimer's disease, and in the brains of sufferers from Down's syndrome when they develop an Alzheimer-like disease in middle life2. This is interesting because Down's syndrome is due to abnormal reduplication of part of the 21st chromosome. Steps in the chemical physiology involved in the laying down of memories and processing information are beginning to be understood. The biochemical expression of individual genes, and their biological activity can be identified on brain slices by using DNA probes for specific messenger RNA. Powerful biochemical and physicalchemical techniques are now being considered with brain imaging techniques such as positron emission tomography, affectionately called PET, and magnetic resonance imaging (MRI) to build up cross sectional pictures of brain activity at different levels. This allows us to visualize and measure biochemical and metabolic changes as they are taking place. Thus it has been possible to localize and measure in schizophrenic patients abnormalities of brain metabolism which only occur during certain types of mental activity. This is the beginning ofa true biology of human cognition. Topographical mapping of electroencephalography (EEG), sometimes called BEAM, or brain electrical activity mapping, gives an instantaneous and non-invasive measure of localized electrical brain wave EEG patterns, so that any association with abnormal psychological or physiological function can be investigated. These developments in our ability to examine brain structure and fimction in the living were un inable a few years ago.
Three decades of psychiatric research A major task of psychiatric research during the 1960s and 1970s was to develop tools to describe and measure accurately the presence and severity of psychiatric symptoms, identify syndromes, and to weed away subjective bias, as well as unwarranted, unsubstantiated, and untetable concepts and theories.
We in this country made a major contribution to the task ofcreating more accurate and powerful tools for such workthe Hamilton Rating Scale, the Present State Examination; Life Events Questionnaires, the General Health Questionnaire and many others. This work grew out of Aubrey Lewis's seed culture which set the standard for tough critical thinking in psychiatry and rejected theory which was not yet supported by evidence. These efforts were not fruitlessa clear understanding developed of the elements of the disease concept and the logic of diagnosis as they apply to different psychiatric conditions, and much was done to identify the role of social and family determinants of psychiatric states, as distinct from genetic and biological ones.
Psychiatry was just behind chest medicine and well in advance ofmost other medical and surgical clinical specialties in learning to use the tools ofepidemiology and statistics. These were used to cut a clear path through the bramble and confusion of ex-cathedra thinking, and to get out of the mire created by our soft data. We were also fortunate to be able to benefit from the serendipitous observations which led to the discoveries ofthe psychotropic action ofbarbiturates, reserpine and chlorpromazine neuroleptic antipsychotics, monoamine oxidase inhibitors, and tricyclic antidepressants. The efficacy of these treatments in psychiatry were proven in randomized double blind clinical trials, and in the early 1970s these drugs became useful tools to probe brain biochemistry and metabolism.
At a more basic level, neuropharmacology provided the first real opening into the neurobiology of psychiatric disorder. However, clinical research in the 1960s and 1970s was mainly concerned with descriptive research. Epidemiology extended clinical observation of the individual to the study of the manifestation of disease in populations. Hand in hand with epidemiology came advances in our understanding ofthe descriptive genes ofpsychiatric illness, the extent to which clinical entities were biologically inherited, and the extent to which physical or social environmental factors played a part.
Clinical genetics, using epidemiological techniques, parents to offspring in schizophrenia, even when the offspring were reared away from the parents at birth. Some of these studies were conducted on a grand scale, such as linking registers, of more than 15 000, which contained all living twins in Denmark with Danish registers of all psychiatric admissions to mental hospitals. But most of these advances in psychiatry could be called descriptive knowledgethe work ofthe botanists of psychiatrybecause they have not given us any understanding of the pathogenesis of clinical entities in the biological sense. At the end of the day, notwithstanding the importance of the environmental influences in predisposing to, and provoking the expression of psychiatric symptoms, or their major importance in influencing the effect of treatment, the major psychiatric disturbances must be based on an underlying abnormality of biological function. Such a view is not a product of our own generation. It was implicit in Euripides' atomistic view of nature, and it was made explicit by Griesinger in his address at the opening of the Clinique for Nervous and Mental Diseases in the Royal Charite in Berlin in 1867. He put it succinctly when he said 'If I were to indicate by one word the point of view from which I form a conception of mental disease, it would be the neuropathological, or rather, the cerebro-pathological.' Unfortunately, the great advances in neuroscience and its technology during the past decade, and the vast numbers of papers which fall under the heading of biological psychiatry since Griesinger's time, have not yet yielded what we might regard as real knowledge or understanding of the pathophysiology of the psychoses.
Argumentthe problem What of the research task in schizophrenia? Implicit in what follows is the notion that advances in the explanation of psychiatric disorders depends on the discoveries ofbasic neuroscience and their biomedical application, but that these depend in turn on well observed and well controlled clinical studies. However, an apparent confusion exists in the literature, with many conflicting results.
Clinical and biological studies of schizophrenia are too numerous to count and so much of this effort has not been very fruitful, but this may be due to the variable nature of the clinical picture and the difficulty relating it to any consistent biological abnormality. The inconsistent results from attempts to measure blood flow and metabolism in the frontal lobe of schizophrenics is one example. Some papers report hypometabolism in the frontal lobe but others, including our study done at the Hammersmith, do not37.
The problem is equally evident when we look at studies of structure (see Figure 1 ). Most imaging studies have reported enlarged ventricles in a small subsample of schizophrenics (that means a shrinkage or failure of development in brain tissue). Other, systematic and well chosen samples have failed to find lateral ventricle or cortical changes8. Histological studies report equally diverse results, for example different groups have found that schizophrenics have atrophy of the vermis9, diminished and distorted hippocampus and other limbic structures without gliosis'0, while others reported. gliosis of the diencephalon and regions of the limbic system" and gliosis of the corpus callosum12, and most recently, It is in fact rare for findings reported in one group ofpatients to be corroborated in the next. But perhaps this is not surprising, given that schizophrenia is a condition in which florid hallucinations and delusions may be chronic, transient or not occur at all, and if present may be mild, or severe, or incapacitating. However, in those cases in which chronic, so called 'negative' symptoms persist after an acute episode has been brought under control, the symptoms are characteristic of those seen in some brain damaged patients; symptoms such as loss of drive, spontaneity, and poverty of affect and content of speech. This distinction of the episodic symptoms vs the enduring ones is most important, as it would be consistent with the notion that functional symptoms based on disturbed physiology can be distinguished from less plastic changes in the hard wiring of the brainperhaps anatomical, or based on other enduring mechanisms. The persisting negative features of schizophrenia hardly respond to medication, but the florid delusions and hallucinations of schizophrenia predictably respond to neuroleptics in most cases. We know that the potency of neuroleptics is closely correlated with their potency in blocking post-synaptic dopamine receptors, which leads to inhibition of dopaminergic synaptic-transmission. However, clinically it is clear that neuroleptics are effective in suppressing hallucinations and delusions in dementia, acute organic brain reaction and manic-depressive psychosis, as well as in schizophrenia. It is, therefore, more likely that the dopamine regulating effects of neuroleptics involve an adjustment of abnormal physiology, by inhibiting a system that is affected by schizophrenia, mania, or brain damage and other conditions, and that behind this there is an underlying disturbance elsewhere in the brain. These well established clinical and pharmacological correlates should make us want to know more about the physiology of the dopamine systemthe function of systems which influence dopaminergic neurons, and, in turn, the action of dopaminergic neurons on the system which they, in turn, influence down stream.
Clinical clues
Are there other clinical clues which can guide us to the possibility of brain dysfunction confined to identifiable circumscribed areas and systems which modulate dopaminergic function? About three years ago a young man was admitted to Charing Cross Hospital who had been'travelling around the world but recently had become passive, apathetic, and lost all vitality and humour. There were no hallucinations or delusions. The admitting doctor diagnosed simple schizophrenia; however, on closer examination there were signs of a cognitive disorder and a magnetic resonance imaging (MRI) scan showed subcortical frontal lobe degeneration. Subsequently AIDS was diagnosed, and a lymphoma was found in the frontal lobes at postmortem examination, as well as subcortical white matter degeneration. The similarity between patients with chronic negative symptoms of schizophrenia and patients with certain frontal lobe lesions has, of course been noted before by Kleist'4,  Walter-Buell5, Klagesl6 Consider what is currently known in terms of neuroanatomy and neurophysiology which might be relevant to schizophrenia. The existence of a mesocortico dopamine tract to the frontal lobe has been established in rats. Dopamine (DA) synthesis was demonstrated in cortical rat brain slices which have adenylate cyclase linked DA receptors18. This was confirmed by observing retrograde transport of fluorescent dye which had been injected into DA projection fields ( Figure 2 ). The fibres are found mainly in deep layers of the frontal, cingulate, pyriform, and entorhinal cortices with their cell bodies originating in the ventral tegmental area (VTA) of the mesencephalon, and in the substantia nigra. These findings have been confirmed in humans and suggest a network which involves a circuit between the mesencephalon of the brain stem, the cortex of frontal lobe and cortices of various parts ofthe limbic system and temporal lobes.
However, we should not solely confime our interest to dopamine. It has been noted that a proportion of cells in rats from the ventral tegmental area innervating the nucleus accumbens contain cholecystokinin (CCK) which co-exists with DA ( Figure 2 ). It has been suggested'8 that some of the ventral tegmental cells innervating the anteromedial cortex ofthe rat could be CCK neurons, since cortical levels of CCK are decreased after electrolytic lesions of the ventral tegmental area. Ablation of glutaminergic fibres from the frontal cortex to the nucleus accumbens fibres led to hypersensitivity of dopamine-sensitive adenylate cyclase, Dl receptors in the rat'9. This is interesting because radioimmune assay of CCK in brain slices of schizophrenics carried out by Roberts and Ferrier9°revealed that those with negative symptoms had decreased CCK in the amygdala and hippocampus, and all schizophrenics showed decreased somatostatin in the hippocampus and decreased CCK in the temporal cortex. De Belleroche, at Charing Cross Hospital, has developed a messenger RNA probe for CCK which can be used to measure the expression of the CCK gene in frontal lobe neurons in postmortem human brain. This application of molecular genetics to a practical neuropathophysiological problem indicates just one way that molecular biology can be used to yield more precise neurophysiological information which could prove relevant to schizophrenia.
Relevance of clinical work to untangling biological results
Given this atomical and physiological account, how can we account for the inconsistence found when researchers try to correlate abnormalities of structure with schizophrenia? Liddle2l and Liddle and Barnes22 working at Charing Cross have made a relevant contribution here. Instead of studying diagnostic subgroups of patients differentiated by severity or prognosis, Liddle studied 40 schizophrenic patients with chronic persistent symptoms. Factor analysis segregated their symptoms into three distinct groups (see Table 1 ). Most symptoms correlated >0.8 with the relevant factors. The first is Psychormotor Poverty syndrome, characterized by poverty of speech, affect and movement. The second is Disorganization syndrome characterized by inappropriate affect and formal thought disorder, and the third is persistent delusions and hallucinations, which Liddle has called the Reality Distortion syndrome. Liddle and Barnes22 replicated the earlier study in a second sample of 57 chronic schizophrenics at Horton Hospital. The success of these studies is probably related to the fact that all patients were included in the study on the basis that they had chronic persistent symptoms. This increases the likelihood of demonstrating an association with an underlying persisting and identifiable brain dysfumction, if indeed there-are syndromes which are the expression of this dysfnction. Note too that they looked for symptom clusters, any one or more ofwhich may occur in a psychotic individual. Thus, a patient could have both the Psychomotor Poverty syndrome and the Disorganization or the Reality Distortion syndrome. They hypothesized that each syndrome is likely to be related to one or more dysfunctional brain areas affecting a system which modulates or controls limbic dopaminergic mechanisms, and therefore results in a reduced functional capacity to control their mechanisms. Thus focusing on syndromesthat is a group ofsymptoms that occur together in different individuals and are persisent in the individual patient over timemay be a more useful strategy: it avoids the unproductive vagaries ofdiagnosis, and suggests a clinical functional entity which, whether it recurs or persists, is likely to be related to an underlying biological dysfunction. What might it be?
Clues to the anatomical site Implications from the Charing Cross work A clinical clue to the possible anatomical localization of the first two of these syndromes is suggested by studies of patients with marked personality changes associated with frontal lobe lesions. Kleist14, and Blumer and Benson23 have identified two frontal lobe syndromes in patients with coarse brain damage: the first consist of apathy, loss of initiative, lack of overt emotion and poverty of speech which they associate with dorso-lateral prefrontal lesions in man. This bears a striking similarity to Liddle's first factor, Psychomotor Poverty syndrome. The second includes overactivity, lack oftact, silly disinhibited behaviour and abnormal speech which they associate with lesions of the orbital prefrontal cortex, although others would locate this in subcortical areas such as the hippocampus and temporal lobe24. This is similar to Liddle's Disorganization syndrome and reminiscent of hebephrenia and chronic thought disorder. These clinical syndromes have also been attributed to abnormal lateralization offunctions; thus the Psychomotor Poverty syndrome has been attributed to left frontal lobe hypofunction while Disorganization and Disinhibition are thought to be due to a lesion in the right frontal lobe2A. Davidson and Bagley's2 wellknown review ofthe evidence from studies ofpatients with focal lesions demonstrate that the syndrome of hallucinations and delusions is most commonly associated with pathology in the medial temporal lobe. Liddle's three syndromes suggest a way out of some of the confusion referred to in earlier literature. In contrast to many other studies which report cortical atrophy or frontal hypofunction in a proportion of schizophrenics with severe chronic symptoms, we could not find evidence of decreased metabolism or cerebral blood flow in the frontal lobes using PET6.
We did find a lack of the asymmetrical metabolism which characterizes noals, whose rate of metabolism is greater in their left frontal lobe than their right. All the studies which found frontal hypometabolism included chronic patients with defect states; this is the group that Liddle would predict to have a frontal lobe lesion. Our PET study only included first admission cases who were previously untreated schizophrenics without the negative symptoms which characterized Liddle's first two factors which we think are related to reduced frontal lobe capacity. The patients in our PET study were suffering mainly from acute hallucinations and delusions. This corresponds to Liddle's Factor m, the Reality Distortion syndrome, which Davidson and Bagley's evidence, for example, would suggest are associated with medial temporal lobe not frontal lobe lesions. Early and colleagues7 have also reported a PET study of 10 newly diagnosed untreated schizophrenics who, like our acute patients, showed no evidence of hypofrontality.
Liddle's concept of three syndromes corresponding to different areas of brain dysfunction is partially supported by the recent report of Kishimoto and colleagues26 who examined brain C-11 glucose metabolism in 20 chronic chizphrenics and 5 controls using PET. Six patients were described as having flat blunted affect and disorganized thinking, consistent with Liddle's Psychomotor Poverty and/or Disorganization syndrome; they had a 38% reduction oftheir mean frontal lobe C-11 glucose activity. Eight patients with delusion and hallucinations had a 26% reduction of C-11 activity in the non-dominant parietal lobe. A third group with a variety of syndromes showed no abnormality on PET. Unfortunately the clinical data in their report is inadequate and doesn't allow us to see how we would further characterize and compare their patients in the light of Liddle's hypothesis. performing the Wisconsin Card Sorting test (WCS test) during xenon-133 inhalation to measure regional cerebral blood flow changes. The WCS test has been reported by Milner28 to be a test of dorsolateral prefrontal function. Figure 3 shows the results during activation with the WCS. It shows the distribution of values for subjects, expressed as a ratio ofthe value of interest divided by blood flow value for the rest of the brain before and during activation. Note that patients did not show the marked increase in dorsolateral prefrontal cerebral blood flow in relation to the overall brain blood flow which was seen in controls. In contrast neither controls nor patients had a significant increase in cerebral blood flow in the prefrontal region during a number matching task (NM) which is not expected to activate prefrontal brain.
In this study patients had been off medication for 4 weeks. The finding was replicated by retesting 17 patients 4 weeks after medication was restarted; the difference between schizophrenics and controls was the same as when they were tested previously, off medication.
The dorsolateral prefrontal (DLPF) cortex corresponds to the area associated with Liddle's Psychomotor Poverty syndrome and the frontal lobe symptoms identified by Kleist and others. In patients, but not controls, those who performed better on the WCS test (i.e. show less defect) had higher prefrontal CBF values, the correlation between prefrontal cerebral blood flow and performance on the WCS score was 0.52 (r=0.52). This supports the contention that poor performance on the WCS test reflects a pathological variation in DLPF blood flow.
Is schizophrenia a developmental disorder?
The dorsolateral prefrontal cortex is said to be a region of neocortex especially in humans, and virtually non-existent in subprimate species.
Weinberger et at27 have pointed out that myelination ofthis region is not complete until the second or third decadeprecisely the time when severe schizophrenia presents itself. Structural changes reported in other brain regions in schizophrenics, such as diminished numbers of limbic and diencephalic neuronal cell bodies'0'" could have occurred as secondary to lesions in the prefrontal or other regions with which there are anatomical links, particularly ifthe primary lesion has occurred during development. The occurrence of both anterograde and retrograde degeneration secondary to a primary lesion are well known, for example in Parkinson's disease. A variation of the theory that dorsolateral prefrontal lesions play a significant role in schizophrenia is the possibility that subcortical neuropathological changes are the primary abnormality and cortical atrophy and cortical DLPF cortical dysfunction are secondary.
Indeed, there are now a number of studies coming from different quarters which suggest that some schizophrenics have significantly smaller limbic and temporal lobe structures. This includes effects on the hippocampus and amygdala reported by Bogerts and colleagues829, areas of the prefrontal cortex, cingulate gyrus and motor cortex reported by Benes et alt30 and a decreased number of cells in the entorhinal and pyriform cortex reported by Jakob and Beckmann'3. All of these areas of the brain link directly or indirectly with the ventral tegmental area, nucleus accumbens, and prefrontal cortex. Moreover, 55 of some 60 CAT scan studies of schizophrenia support the proposition that brain tissue is diminished in chronic patients29. Several groups13,3133 have found a decrease in cell density as well as a decrease in volume of tissuel3'30-32. This occurs in the absence of gliosis, which we would expect if degeneration occurred after the first year of life and is consistent with the hypothesis that a degree of agenesis of nerve fibres occurs in schizophrenia. Bogert's controlled study of 54 chronic schizophrenics measured brain tissue reduction by CT scans and found that the left sylvian fissure width indicated the most affected area; it was enlarged by 79-233% (unpublished). There was no correlation between the degree of deformity and the patient's length of illness, suggesting that the deformity is present before the illness begins.
Links between limbic, temporal and frontal lobe hypometabolism: further evidence from animal physiology The evidence of frontal hypometabolism during positron emission tomography (PET) in chronic (but not acute) schizophrenia also supports the proposition that there is a limbic-temporal-frontal abnormality involved in those schizophrenics who have a chronic syndrome.
Thus the theory suggests that the functional changes, such as hallucinations and delusions which we see in acute relapse, could be explained as a failure of prefrontal control of limbic function when under stress. There is experimental evidence in animals to support this. The resulting dopaminergic overactivity would be ascribed to a failure of prefrontal control which is modulated by neuroleptic medication which we know inhibits the dopamine system. Studies on rats referred to above support such a theory.
Pykock33 has demonstrated that 6-hydroxy lesions ofprefrontal cortex in rats lead to disinhibition ofthe DA system in the nucleus accumbens and striatum. Gunne and colleagues34 have reported mesolimbic supersensitivity following prefrontal lesions: this could be a model for the production offlorid psychotic symptoms and their response to neuroleptics. Support for the relevance of these findings in humans was produced by Whalley and colleagues-5 who found that acute untreated psychotic patients with Schneider's First Rank symptoms had increased dopaminergic responsiveness, as indicated by an increased growth hormone response and prolactin suppression following 0.75 mg (subcutaneous) apomorphine, a dopamine agonist. If corroborated these results would suggest either a lack of inhibition of the limbic system from higher centres in this group of patients, or an increased responsiveness of the limbic system, for example due to increased post synaptic receptors, which again could be a consequence of too little tonic inhibition from higher centres. Some of the reported neuropathological studies, such as the findings of Jacob and Beckmann of a paucity of cell bodies in the entorhinal cortex and parahippocampal gyrus could be consistent with this model. Dysgenesis (or a failure of normal cell growth during development of cells) in the entorhinal cortex, with its prefrontal and limbic connections, could similarly lead to a failure of control over limbic dopaminergic function from higher centres. This is speculative, and these matters are never so simple -Crow's group failed to corroborate Whalley's findings; but this may be because of differences in case selection (personal communication).
Future directions for schizophrenia research Although a picture is beginning to emerge ofreduced numbers of neurons per unit volume in the prefrontal, limbic, and temporal areas, these results are, at best, tentative. Some of the brains included in the histological studies I have mentioned had been stored since the 1920s. The method for quantifying cell loss has not always been reliable or exact. No systematic ascertainment ofsymptoms or detailed characterization using standardized criteria of the clinical picture acquired prior to death is available for any of these studies. A similar criticism can be made of data published from imaging and biochemical studies. If symptom clusters are related to abnormalities in different brain sites, careful clinical characterization needs to be combined with neurobiological studies in order to elucidate the relationship.
Insufficient detail about patient selection is a serious limitation of reports to date, but this is not surprising as this is a major problem plaguing clinical psychiatric research. In fact, factors relating to patient-selection account for as much ofthe variance in the outcome oftreatment in psychiatry, as the use of active medication versus placebo3'. This is because of the wide variability in the course of psychiatric disorders; from spontaneous remission to a total failure of response to treatment. As we have seen, Liddle's work hints at a possible source of this variation within schizophrenia. Thus we need to focus the neurobiological sciences on schizophrenia research.
Conclusionorganization of research
in relation to psychiatry Out ofthe vast potential for focusing neurobiological science on the clinical problems of psychiatry, these examples give some indication of the interplay between basic research and clinical research which can enable us to take advantage of nature's experiments, and conduct our own. Each has something to contribute to the other. Similarly so for the neurosciences themselvesprobably in no other field do different disciplines coalesce to such a degree.
Because most individuals' research interests tend to gravitate towards the centre of his or her own specialty, rather than the borders which link with others, we must constantly strive to facilitate the exchange of information and ideas between disciplines. One way to do this is to selectively direct financial support in each discipline towards collaborative projects with other disciplines. One would like to see groups from a variety of disciplines meeting regularly to inform each other of their work and discuss possible collaboration.
Recognizing the, need for workers to stay in touch with mainstream developments of their own discipline, I would agree with an attitude which encourages each discipline to have a core of the mainstream activities of their field group going on in their department. The problems of promoting cross discipline collaboration might be addressed by reserving say a third of the funding available to departments in medical schools, and postgraduate and research institutions, to be allocated as grants within the institution for cross discipline collaborative research which is clinically related. If about a third of each department's funding were contingent on such collaborative links with other departments to put forward projects which are directed toward clinical issues, I believe this type of development would flourish.
Ultra empiricismtime for a change?
We began with a brief overview of postwar psychiatric research. Attention was drawn to the development of clinical research methods which yield reliable data. Until recently the emphasis has been on descriptive research using clinical, genetic and epidemiological approaches to characterize the symptoms and syndromes which are the focus of interest in our specialty, but this has occurred in the relative absence oftheoretical thinking. The influence ofAubrey Lewis enabled us to clear from our field of vision unsubstantiated and untestable concepts, but our enthusiasm led us to adopt the dictum 'If there is no evidence it does not exist'. Research proceeded piecemeal, project by project, without a substantial theoretical basetheorizing and conceptual thinking was discouraged. More recently, neurobiology has opened the way for a renaissance of opportunity which must be grasped by psychiatry. Griesinger's conception of mental disease as 'neuropathological' or 'cerebropathological' is too narrow. I would suggest 'neurobiological' instead. We are rapidly acquiring a background of basic data which can be fitted to clinical models to create theories which can guide our thinking. It is time for us to encourage our colleagues to step back from the ultra empiricist approach which has served British psychiatry so well, and make room for more speculative, conceptual thinkingtheoretical formulations which gather up the data in an ordered fashion and yield predictions which will test our theories and gradually reshape our understanding as science progresses. We are now entering the era of neurobiological psychiatry, and this more than any other field requires cQllaboration across disciplines. This is essential for research in schizophrenia.
